# Enanta Pharmaceuticals, Inc. (ENTA)

> Source: Nexqual · https://nexqual.com/ENTA · data as of 2026-11-18 20:52 UTC · cite as "Nexqual, Enanta Pharmaceuticals, Inc. (ENTA), nexqual.com/ENTA" · informational, not investment advice.

**Price:** USD 8.16 (-6.10% today) · US market open, as of November 18, 2026 at 20:52 UTC; quotes may be delayed. Prev close 8.69 · day 8.1–8.75 · 52w 8.1–17.15 · market cap $238M · NMS

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $65.3M, net income -$63.2M (-96.9% margin), free cash flow -$36.9M (SEC filings).
- Total return with dividends: 1Y -34.1% vs S&P 500 +11.9%; 5Y -89.2% vs S&P 500 +66.7%.
- Next earnings: 2027-02-08 (date not yet confirmed by the company), EPS estimate USD -0.77, revenue estimate $14.3M.
- Dividend: ENTA paid no cash dividend in the last five years.
- Short interest: 7.63% of float (as of 2026-10-30), 7.0 days to cover.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $97.1M | $86.2M | $79.2M | $67.6M | $65.3M | $65.3M |
| Operating income | -$110M | -$124M | -$137M | -$122M | -$85.3M | -$58.7M |
| Net income | -$79.0M | -$122M | -$134M | -$116M | -$81.9M | -$63.2M |
| EPS (diluted) | -$3.92 | -$5.91 | -$6.38 | -$5.48 | -$3.84 | — |
| Free cash flow | -$70.7M | -$86.9M | -$112M | -$96.7M | -$32.2M | -$36.9M |
| Operating margin | -112.9% | -143.7% | -173.2% | -179.9% | -130.7% | -90.0% |
| Net margin | -81.4% | -141.3% | -169.0% | -171.6% | -125.4% | -96.9% |
| Revenue growth | -20.7% | -11.2% | -8.1% | -14.6% | -3.4% | — |
| Cash + short-term investments | $244M | $249M | $370M | $248M | $189M | — |
Fiscal years end Sep. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)


## Analysts
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-23 | HC Wainwright & Co. | Reiterated | Buy | $20 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-11-18) | 5Y (from 2021-11-15) |
|---|---|---|
| Total return | -34.1% | -89.2% |
| S&P 500 (SPY) | +11.9% | +66.7% |
| Per year | -34.2% | -35.9% |
| Volatility (annualized) | 53.5% | 66.3% |
| Max drawdown | -51.7% (Dec 2025→Nov 2026) | -94.9% (Nov 2021→Apr 2025) |

## Dividends
ENTA paid no cash dividend in the last five years.

## Short interest
1,856,510 shares sold short, 7.63% of the float, as of Oct 30, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 30, 2026): 2,552,994 shares (-27.3%). Days to cover: 7.0 (short shares ÷ average daily volume).

## Peers (Biotechnology)
KOD (Kodiak Sciences Inc) USD 97.7 +0.93% · BLTE (Belite Bio, Inc) USD 156.45 -0.81% · ORKA (Oruka Therapeutics, Inc.) USD 95.68 -0.67% · IBRX (ImmunityBio, Inc.) USD 6.7 +6.95% · IMVT (Immunovant, Inc.) USD 33.24 +0.08% · CGON (CG Oncology, Inc.) USD 79.85 +1.15%

## More
Full page: https://nexqual.com/ENTA · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)

Named in ENTA's own 10-K filed 2026-11-18 (https://www.sec.gov/Archives/edgar/data/1177648/000119312526466170/enta-20260930.htm):

| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | AbbVie (ABBV) | "We discovered glecaprevir, the second of two antiviral protease inhibitors developed through our collaboration with AbbVie for the treatment of acute or chronic infection with hepatitis C virus, or HCV." |
| Competitor | Merck (MRK) | "AbbVie's MAVYRET/MAVIRET regimen currently competes in various geographic markets and HCV patient populations with Gilead's Epclusa® (a fixed dose combination of sofosbuvir and velpatasvir), Vosevi® (a fixed-dose combina…" |

## Company outlook (8-K filed 2026-11-16)

- "Topline Data Expected in 1Q 2027 • Initiated Dosing in RESOLVE, a Phase 2b/3 Trial of Zelicapavir in Adult Patients at High-Risk of Severe RSV Outcomes;"
- "Topline Phase 2b Data Expected in 2027 • Topline Data from Phase 1 Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, Now Expected in 1Q 2027 • Investigational New Drug (IND) Application Filing for EDP-903, an Oral, Once-Daily STAT6 Inhibitor, Now Expected in 2Q 2027 • Selected MRGPRX2 Development Candidate EPS-5336 for the Treatment of Mast Cell-Driven Diseases Including Migraine;"
- "Kieffer, Ph.D. to Chief Operating Officer • Cash and Marketable Securities Totaling $194.5 Million at September 30, 2026, as well as Continuing Retained Royalties, with Cash Runway Expected to Fund Operations into Fiscal 2029 WATERTOWN, Mass., November 16, 2026 – Enanta Pharmaceuticals, Inc."
- "In RSV, we completed enrollment in LOTUS, a Phase 2b trial of zelicapavir in pediatric patients, with topline data expected in the first quarter of 2027."

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-12-31) | $-0.77 | $-0.41 | −$0.36 | $14.3M | 1 |
| Next quarter (ends 2027-03-31) | $-0.83 | $-0.47 | −$0.36 | $12.5M | 1 |
| Current fiscal year (ends 2027-09-30) | $-3.19 | $-2.37 | −$0.82 | $64.1M | 2 |
| Next fiscal year (ends 2028-09-30) | $-2.27 | $-1.91 | −$0.36 | $86.4M | 4 |

## Options: expected move (Cboe, 15-min delayed)

Expected move by 2027-04-16 (includes earnings 2027-02-08): ±57.5%; last 8 reports averaged ±6.3%.

| Expiration | Days | ATM IV | Expected move |
|---|---|---|---|
| 2026-11-20 | 2 | 235.1% | ±27.3% |
| 2027-01-15 | 58 | 121.6% | ±18.4% |
| 2027-04-16 | 149 | 96.7% | ±57.5% |

## Earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| Nov 16, 2026 | Quarter ended Sep 30, 2026 | −$0.81 | −$0.77 | Miss −5.2% | -20.9% |
| Aug 10, 2026 | Quarter ended Jun 30, 2026 | −$0.67 | −$0.53 | Miss −26.4% | -1.8% |
| May 11, 2026 | Quarter ended Mar 31, 2026 | −$0.45 | −$0.57 | Beat +21.1% | -5.3% |
| Feb 9, 2026 | Quarter ended Dec 31, 2025 | −$0.42 | −$0.80 | Beat +47.5% | +4.6% |
| Nov 17, 2025 | — | — | — | — | +2.5% |
| Aug 11, 2025 | — | — | — | — | -0.6% |
| May 12, 2025 | — | — | — | — | -0.8% |
| Feb 10, 2025 | — | — | — | — | +14.1% |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

## Recent SEC filings (last 120 days)
| Filed | Form | What it says | Filing |
|---|---|---|---|
| 2026-11-18 | 10-K | Annual report · period ended Sep 30, 2026 | https://www.sec.gov/Archives/edgar/data/1177648/000119312526466170/0001193125-26-466170-index.htm |
| 2026-11-16 | Schedule 13G | ADAR1 Capital Management, LLC, Daniel Schneeberger: 6.0% of shares, passive 5%+ holder | https://www.sec.gov/Archives/edgar/data/1177648/000110465926128729/0001104659-26-128729-index.htm |
| 2026-11-16 | 8-K | Quarterly results | https://www.sec.gov/Archives/edgar/data/1177648/000119312526463508/0001193125-26-463508-index.htm |
| 2026-11-16 | Schedule 13G/A | Farallon Capital Management, L.L.C., Dapice Joshua J.: 3.3% of shares, passive 5%+ holder (amended) | https://www.sec.gov/Archives/edgar/data/1177648/000090883426000532/0000908834-26-000532-index.htm |
| 2026-10-29 | 8-K | Other material event — “As previously disclosed, Enanta Pharmaceuticals, Inc. (the "Company") filed a patent infringement action in the Unified Patent Court (the "UPC") of the European Union against Pfizer Inc. and certain of its subsidiaries, seeking a determination of liability for infringement of European Patent No. EP 4 051 265 (the " 265 Patent") in connection with Pfizer's manufacture, use, and sale of Paxlovid (nirmatrelvir tablets; ritonavir tablets) in the 18 EU member states participating in the UPC. Pfizer counterclaimed for…” | https://www.sec.gov/Archives/edgar/data/1177648/000119312526437774/0001193125-26-437774-index.htm |
| 2026-10-28 | 8-K | Director or executive officer change, or pay arrangement; Regulation FD disclosure — “On October 28, 2026, Enanta Pharmaceuticals, Inc. (the "Company") and Jay R. Luly, Ph.D., age 70, announced Dr. Luly's intention to retire as President and Chief Executive Officer by February 1, 2027, following 23 years of leadership with the Company. The Company expects to enter into an agreement with Dr. Luly for his continued service as a strategic advisor for the remainder of 2027. The Board of Directors (the "Board") of the Company has initiated a comprehensive search for Dr. Luly's successor, considering…” | https://www.sec.gov/Archives/edgar/data/1177648/000119312526435092/0001193125-26-435092-index.htm |
| 2026-10-27 | Schedule 13G | BlackRock Portfolio Management LLC: 5.4% of shares, passive 5%+ holder | https://www.sec.gov/Archives/edgar/data/1177648/000205211326001073/0002052113-26-001073-index.htm |
| 2026-08-14 | Schedule 13G/A | Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd.: 5.0% of shares, passive 5%+ holder (amended) | https://www.sec.gov/Archives/edgar/data/1177648/000117266126003479/0001172661-26-003479-index.htm |
| 2026-08-14 | Schedule 13G/A | Farallon Capital Management, L.L.C., Farallon Capital Partners, L.P.: 8.3% of shares, passive 5%+ holder (amended) | https://www.sec.gov/Archives/edgar/data/1177648/000090883426000416/0000908834-26-000416-index.htm |
| 2026-08-12 | 10-Q | Quarterly report · period ended Jun 30, 2026 | https://www.sec.gov/Archives/edgar/data/1177648/000119312526345719/0001193125-26-345719-index.htm |
| 2026-08-10 | 8-K | Quarterly results | https://www.sec.gov/Archives/edgar/data/1177648/000119312526342336/0001193125-26-342336-index.htm |
Source: SEC EDGAR. Quotes are the opening words of each item as filed.
